INS and diabetes mellitus: In the cohort of IA patients with diabetes, time-varying sulfonylurea (HR 1.77, 95% CI 1.40–2.25, p < 0.001) and insulin use (HR 5.95, 95% CI 4.68–7.57, p < 0.001) were associated with increased risk of MACE, whereas metformin was related to reduced risk (HR 0.69 95% CI 0.54–0.88, p = 0.003) in the univariate analysis (Supplementary Table 7).